Atara Biotherapeutics (ATRA) Total Non-Current Liabilities (2013 - 2026)

Atara Biotherapeutics' Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $55.5 million for Q1 2026.

• Quarterly Total Non-Current Liabilities fell 51.33% year-over-year to $55.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.5 million (down 51.33% YoY) and the FY2025 annual result came in at $56.9 million, down 71.97% from the prior year.
• Total Non-Current Liabilities was $55.5 million for Q1 2026 at Atara Biotherapeutics, down from $56.9 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $260.1 million in Q4 2023 and bottomed at $31.2 million in Q2 2025.
• A 5-year average of $174.4 million and a median of $203.1 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 40.11% — and 2025, when it tumbled 86.09%.
• Atara Biotherapeutics' Total Non-Current Liabilities stood at $244.2 million in 2022, then rose by 6.51% to $260.1 million in 2023, then retreated by 21.91% to $203.1 million in 2024, then plunged by 71.97% to $56.9 million in 2025, then retreated by 2.57% to $55.5 million in 2026.
• Business Quant data shows ATRA's Total Non-Current Liabilities at $55.5 million in Q1 2026, $56.9 million in Q4 2025, and $65.0 million in Q3 2025.